Ibandronate (Sodium Monohydrate)

Ibandronate Sodium Monohydrate (BM-210955; RPR-102289A) is an orally active, selective inhibitor of farnesyl pyrophosphate synthase (FPP synthase) . Ibandronate Sodium Monohydrate can block the mevalonate pathway to inhibit the isoprenylation modification of small GTPases (such as RAS, RHO family proteins), induce tumor cell apoptosis and inhibit bone resorption. Ibandronate Sodium Monohydrate inhibits tumor cell proliferation (such as ER+ breast cancer cells), promotes the expression of the pro-apoptotic gene FAS, and can produce synergistic anti-tumor effects with anti-estrogen compounds. Ibandronate Sodium Monohydrate is used in the study of osteoporosis and bone metastatic tumors (such as breast cancer bone metastasis) [1][2][3][4].

Product Specifications

CAS Number

[138926-19-9]

Product Name Alternative

BM-210955; RPR-102289A

UNSPSC

12352211

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis

Type

Reference compound

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/Ibandronate-Sodium-Monohydrate.html

Concentration

10mM

Purity

98.0

Solubility

DMSO : < 1 mg/mL (ultrasonic; warming; heat to 80°C) |H2O : 25 mg/mL (ultrasonic)

Smiles

OC(P(O)(O)=O)(P(O)(O[Na])=O)CCN(C)CCCCC.O

Molecular Formula

C9H24NNaO8P2

Molecular Weight

359.23

Precautions

H302, H315, H319, H335

References & Citations

[1]Journe F, et al. Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines. Breast Cancer Res. 2006;8 (1) :R2.|[2]Thaler R, et al. Ibandronate increases the expression of the pro-apoptotic gene FAS by epigenetic mechanisms in tumor cells. Biochem Pharmacol. 2013 Jan 15;85 (2) :173-85.|[3]Pfister T, et al. The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats. Toxicology. 2003 Sep 30;191 (2-3) :159-67.|[4]Russell RG. Ibandronate: pharmacology and preclinical studies. Bone. 2006 Apr;38 (4 Suppl 1) :S7-12.